Clinical trial

A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT06215755

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention VRG50635 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study of VRG50635 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2024-01-15

PhasePHASE1

Conditions

Amyotrophic Lateral Sclerosisverified · MONDO: amyotrophic lateral sclerosis

Interventions

VRG50635DRUG

Sponsors & collaborators

Verge Genomicslead sponsor

Mapped research locations

MontrealQuebec, Canada2 UtrechtNetherlands1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06215755 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.